lorazepam has been researched along with Kidney Failure in 3 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While some case reports indicate that high doses of propylene glycol (PG) may result in metabolic acidosis, there has been no large-scale study that evaluated the risk of metabolic acidosis in patients receiving PG-containing benzodiazepines for acute alcohol withdrawal." | 3.88 | Assessing Propylene Glycol Toxicity in Alcohol Withdrawal Patients Receiving Intravenous Benzodiazepines: A One-Compartment Pharmacokinetic Model. ( Bodreau, C; Elbarbry, F; Farthing, K; Jahn, A, 2018) |
| "We previously verified a physiologically based pharmacokinetic (PBPK) model for mirabegron in healthy subjects using the Simcyp Simulator by incorporating data on the inhibitory effect on cytochrome P450 (CYP) 2D6 and a multi-elimination pathway mediated by CYP3A4, uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B7 and butyrylcholinesterase (BChE)." | 1.51 | Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. ( Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K, 2019) |
| "Case 1: A 15-year-old boy with chronic renal failure on hemodialysis developed acute headache, hypertension, vomiting, and blurred vision followed by severe visual impairment and a secondarily generalized clonic seizure." | 1.39 | Status epilepticus amauroticus and posterior reversible encephalopathy syndrome in children. ( Connolly, MB; Huh, L; Muro, VL; Yip, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jahn, A | 1 |
| Bodreau, C | 1 |
| Farthing, K | 1 |
| Elbarbry, F | 1 |
| Konishi, K | 1 |
| Minematsu, T | 1 |
| Nagasaka, Y | 1 |
| Tabata, K | 1 |
| Muro, VL | 1 |
| Yip, S | 1 |
| Huh, L | 1 |
| Connolly, MB | 1 |
3 other studies available for lorazepam and Kidney Failure
| Article | Year |
|---|---|
Assessing Propylene Glycol Toxicity in Alcohol Withdrawal Patients Receiving Intravenous Benzodiazepines: A One-Compartment Pharmacokinetic Model.
Topics: Acid-Base Equilibrium; Acidosis; Alcoholism; Benzodiazepines; Diazepam; Female; Humans; Injections, | 2018 |
Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aging; Butyrylcholineste | 2019 |
Status epilepticus amauroticus and posterior reversible encephalopathy syndrome in children.
Topics: Adolescent; Anticonvulsants; beta-Thalassemia; Blindness; Bone Marrow Transplantation; Child; Diffus | 2013 |